TY - JOUR AU - Monagle, P. AU - Chan, A. K. AU - Goldenberg, N. A. AU - Ichord, R. N. AU - Journeycake, J. M. AU - Nowak-Gottl, U. PY - 2012 DA - 2012// TI - Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines JO - Chest VL - 141 UR - https://doi.org/10.1378/chest.11-2308 DO - 10.1378/chest.11-2308 ID - Monagle2012 ER - TY - JOUR AU - Conroy, S. AU - Choonara, I. AU - Impicciatore, P. AU - Mohn, A. AU - Arnell, H. AU - Rane, A. PY - 2000 DA - 2000// TI - Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children JO - Br Med J VL - 320 UR - https://doi.org/10.1136/bmj.320.7227.79 DO - 10.1136/bmj.320.7227.79 ID - Conroy2000 ER - TY - JOUR AU - Conroy, S. AU - McIntyre, J. PY - 2005 DA - 2005// TI - The use of unlicensed and off-label medicines in the neonate JO - Semin Fetal Neonatal Med VL - 10 UR - https://doi.org/10.1016/j.siny.2004.11.003 DO - 10.1016/j.siny.2004.11.003 ID - Conroy2005 ER - TY - JOUR AU - Choonara, I. PY - 2004 DA - 2004// TI - Unlicensed and off-label drug use in children: implications for safety JO - Expert Opin Drug Saf VL - 3 UR - https://doi.org/10.1517/14740338.3.2.81 DO - 10.1517/14740338.3.2.81 ID - Choonara2004 ER - TY - JOUR AU - Cuzzolin, L. AU - Atzei, A. AU - Fanos, V. PY - 2006 DA - 2006// TI - Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety JO - Expert Opin Drug Saf VL - 5 UR - https://doi.org/10.1517/14740338.5.5.703 DO - 10.1517/14740338.5.5.703 ID - Cuzzolin2006 ER - TY - JOUR AU - Jong GW, T. AU - Vulto, A. G. AU - de Hoog, M. AU - Schimmel, K. J. AU - Tibboel, D. AU - van den Anker, J. N. PY - 2001 DA - 2001// TI - A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital JO - Pediatrics VL - 108 UR - https://doi.org/10.1542/peds.108.5.1089 DO - 10.1542/peds.108.5.1089 ID - Jong GW2001 ER - TY - JOUR AU - Roberts, R. AU - Rodriguez, W. AU - Murphy, D. AU - Crescenzi, T. PY - 2003 DA - 2003// TI - Pediatric drug labeling: improving the safety and efficacy of pediatric therapies JO - JAMA VL - 290 UR - https://doi.org/10.1001/jama.290.7.905 DO - 10.1001/jama.290.7.905 ID - Roberts2003 ER - TY - JOUR AU - Zhao, P. AU - Zhang, L. AU - Grillo, J. A. AU - Liu, Q. AU - Bullock, J. M. AU - Moon, Y. J. PY - 2011 DA - 2011// TI - Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review JO - Clin Pharmacol Ther VL - 89 UR - https://doi.org/10.1038/clpt.2010.298 DO - 10.1038/clpt.2010.298 ID - Zhao2011 ER - TY - STD TI - Committee for Medicinal Products for Human Use. Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. 2006. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003066.pdf [accessed 26 April 2018]. UR - http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003066.pdf ID - ref9 ER - TY - STD TI - US Food and Drug Administration. Summary minutes of the advisory committee for pharmaceutical science and clinical pharmacology meeting march 14, 2012. 2012. Available from: https://wayback.archive-it.org/7993/20170404154933/https:/www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM306989.pdf [accessed 2 May 2018]. UR - https://wayback.archive-it.org/7993/20170404154933/https:/www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM306989.pdf ID - ref10 ER - TY - JOUR AU - Wagner, C. AU - Zhao, P. AU - Pan, Y. AU - Hsu, V. AU - Grillo, J. AU - Huang, S. M. PY - 2015 DA - 2015// TI - Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK JO - CPT Pharmacometrics Syst Pharmacol VL - 4 UR - https://doi.org/10.1002/psp4.33 DO - 10.1002/psp4.33 ID - Wagner2015 ER - TY - JOUR AU - Strougo, A. AU - Eissing, T. AU - Yassen, A. AU - Willmann, S. AU - Danhof, M. AU - Freijer, J. PY - 2012 DA - 2012// TI - First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development JO - J Pharmacokinet Pharmacodyn VL - 39 UR - https://doi.org/10.1007/s10928-012-9241-9 DO - 10.1007/s10928-012-9241-9 ID - Strougo2012 ER - TY - JOUR AU - Willmann, S. AU - Becker, C. AU - Burghaus, R. AU - Coboeken, K. AU - Edginton, A. AU - Lippert, J. PY - 2014 DA - 2014// TI - Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban JO - Clin Pharmacokinet VL - 53 UR - https://doi.org/10.1007/s40262-013-0090-5 DO - 10.1007/s40262-013-0090-5 ID - Willmann2014 ER - TY - STD TI - Bayer AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. 2018. [Cited 24 April 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf ID - ref14 ER - TY - STD TI - Janssen Pharmaceuticals Inc. Xarelto® (rivaroxaban) Prescribing Information. 2017. [Cited 26 April 2018]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf. UR - http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf ID - ref15 ER - TY - JOUR AU - Attard, C. AU - Monagle, P. AU - Kubitza, D. AU - Ignjatovic, V. PY - 2012 DA - 2012// TI - The in vitro anticoagulant effect of rivaroxaban in children JO - Thromb Res VL - 130 UR - https://doi.org/10.1016/j.thromres.2012.07.009 DO - 10.1016/j.thromres.2012.07.009 ID - Attard2012 ER - TY - JOUR AU - Attard, C. AU - Monagle, P. AU - Kubitza, D. AU - Ignjatovic, V. PY - 2014 DA - 2014// TI - The in-vitro anticoagulant effect of rivaroxaban in neonates JO - Blood Coagul Fibrinolysis VL - 25 UR - https://doi.org/10.1097/MBC.0000000000000033 DO - 10.1097/MBC.0000000000000033 ID - Attard2014 ER - TY - STD TI - Kubitza D, Willmann S, Becka M, Thelen K, Young G, Brandão LR, et al. Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. Thrombosis J. 2018. ID - ref18 ER - TY - JOUR AU - Rohde, G. PY - 2008 DA - 2008// TI - Determination of rivaroxaban – a novel, oral, direct factor Xa inhibitor – in human plasma by high-performance liquid chromatography-tandem mass spectrometry JO - J Chromatogr B Analyt Technol Biomed Life Sci VL - 872 UR - https://doi.org/10.1016/j.jchromb.2008.07.015 DO - 10.1016/j.jchromb.2008.07.015 ID - Rohde2008 ER - TY - JOUR AU - Mueck, W. AU - Becka, M. AU - Kubitza, D. AU - Voith, B. AU - Zuehlsdorf, M. PY - 2007 DA - 2007// TI - Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in healthy subjects JO - Int J Clin Pharmacol Ther VL - 45 UR - https://doi.org/10.5414/CPP45335 DO - 10.5414/CPP45335 ID - Mueck2007 ER - TY - JOUR AU - Mueck, W. AU - Lensing, A. W. A. AU - Agnelli, G. AU - Décousus, H. AU - Prandoni, P. AU - Misselwitz, F. PY - 2011 DA - 2011// TI - Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention JO - Clin Pharmacokinet VL - 50 UR - https://doi.org/10.2165/11595320-000000000-00000 DO - 10.2165/11595320-000000000-00000 ID - Mueck2011 ER - TY - JOUR AU - Buller, H. R. AU - Lensing, A. W. A. AU - Prins, M. H. AU - Agnelli, G. AU - Cohen, A. AU - Gallus, A. S. PY - 2008 DA - 2008// TI - A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study JO - Blood VL - 112 UR - https://doi.org/10.1182/blood-2008-05-160143 DO - 10.1182/blood-2008-05-160143 ID - Buller2008 ER - TY - JOUR AU - Agnelli, G. AU - Gallus, A. AU - Goldhaber, S. Z. AU - Haas, S. AU - Huisman, M. V. AU - Hull, R. D. PY - 2007 DA - 2007// TI - Treatment of proximal deep-vein thrombosis with the Oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study JO - Circulation VL - 116 UR - https://doi.org/10.1161/CIRCULATIONAHA.106.668020 DO - 10.1161/CIRCULATIONAHA.106.668020 ID - Agnelli2007 ER -